Cargando…

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells

INTRODUCTION: The presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell-like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, to be able to disseminate and metastasize, CTC must be able to perfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasimir-Bauer, Sabine, Hoffmann, Oliver, Wallwiener, Diethelm, Kimmig, Rainer, Fehm, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496132/ https://www.ncbi.nlm.nih.gov/pubmed/22264265 http://dx.doi.org/10.1186/bcr3099

Ejemplares similares

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2009)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple‐negative breast cancer patients
por: Bittner, Ann‐Kathrin, et al.
Publicado: (2020)

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
por: Chebouti, Issam, et al.
Publicado: (2016)

Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients
por: Krawczyk, Natalia, et al.
Publicado: (2014)

In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2022)

Association of Soluble B7-H4 and Circulating Tumor Cells in Blood of Advanced Epithelial Ovarian Cancer Patients
por: Mach, Pawel, et al.
Publicado: (2021)

Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients
por: Keup, Corinna, et al.
Publicado: (2021)

Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2020)

Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients
por: Keup, Corinna, et al.
Publicado: (2020)

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
por: Kuhlmann, Jan Dominik, et al.
Publicado: (2012)

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy
por: Chebouti, Issam, et al.
Publicado: (2017)

Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay
por: Fehm, Tanja, et al.
Publicado: (2012)

Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers
por: Wu, Shiyang, et al.
Publicado: (2015)

Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer
por: Schwich, Esther, et al.
Publicado: (2019)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
por: Keup, Corinna, et al.
Publicado: (2023)

Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2021)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma
por: Lengerke, Claudia, et al.
Publicado: (2011)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Co-Expression of Stem Cell and Epithelial Mesenchymal Transition Markers in Circulating Tumor Cells of Bladder Cancer Patients
por: Zhang, Ruiyun, et al.
Publicado: (2020)

Image-Based Identification and Genomic Analysis of Single Circulating Tumor Cells in High Grade Serous Ovarian Cancer Patients
por: Salmon, Carolin, et al.
Publicado: (2021)

Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
por: König, Lisa, et al.
Publicado: (2019)

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment
por: Bredemeier, Maren, et al.
Publicado: (2016)

Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
por: Moukas, Stefanos Ioannis, et al.
Publicado: (2023)

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2009)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer
por: Chebouti, Issam, et al.
Publicado: (2016)

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Keup, Corinna, et al.
Publicado: (2019)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer
por: Bredemeier, Maren, et al.
Publicado: (2017)

The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells
por: Kölbl, Alexandra C., et al.
Publicado: (2016)

The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
por: Hartkopf, Andreas Daniel, et al.
Publicado: (2013)

Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse
por: Hoffmann, Oliver, et al.
Publicado: (2022)

Circulating tumor cells with epithelial-mesenchymal transition markers as potential biomarkers for the diagnosis of lung cancer
por: Jiang, Sha-Sha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4q3da17ei57u4e1vadsohcknf9